Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Pharmacol Ther. 2019 Feb 10;197:212–224. doi: 10.1016/j.pharmthera.2019.02.001

Figure 2. RvD1 is decreased in COPD patients.

Figure 2.

Panels A and B: RvD1 was measured in bronchoalveolar lavage fluid (BAL) and serum from non-smokers without COPD and from COPD patients by EIA as previously reported (Croasdell, et al., 2015). Panel C: Levels of eicosanoid oxidoreductase (EOR), an enzyme that degrades and inactivates RvD1, were measured in lung tissue from non-smoking donors or COPD patients, as previously reported (Hsiao, et al., 2015).